|Assessment Status||Rapid Review Complete|
|Indication||As monotherapy is indicated for the treatment of relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin.|
|Rapid review commissioned||22/11/2016|
|Rapid review completed||18/01/2017|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.|
The HSE has approved reimbursement following confidential price negotiations October 2017.